ESMO Gastrointestinal Cancers Congress 2024

Share on: 

Research coauthored by RTI Health Solutions experts will be presented at ESMO Gastrointestinal Cancers Congress 2024
 

Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. Taieb J, Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh K-H, Cremolini C, Wang J, Tran Q, Chao J, Chen Z, Pietrantonio F. Poster

Related Services